Compare OTEX & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OTEX | CYTK |
|---|---|---|
| Founded | 1991 | 1997 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 8.3B |
| IPO Year | 1998 | 2004 |
| Metric | OTEX | CYTK |
|---|---|---|
| Price | $25.01 | $61.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 17 |
| Target Price | $37.50 | ★ $86.12 |
| AVG Volume (30 Days) | ★ 2.8M | 1.7M |
| Earning Date | 05-05-2026 | 05-25-2026 |
| Dividend Yield | ★ 4.49% | N/A |
| EPS Growth | N/A | ★ 3.49 |
| EPS | ★ 1.24 | N/A |
| Revenue | ★ $2,815,241,000.00 | $13,368,000.00 |
| Revenue This Year | $2.80 | $37.53 |
| Revenue Next Year | $1.05 | $214.81 |
| P/E Ratio | $19.74 | ★ N/A |
| Revenue Growth | ★ 22.88 | N/A |
| 52 Week Low | $22.44 | $29.31 |
| 52 Week High | $39.90 | $70.98 |
| Indicator | OTEX | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 43.87 | 42.82 |
| Support Level | $22.44 | $59.23 |
| Resistance Level | $28.60 | $65.93 |
| Average True Range (ATR) | 0.98 | 2.55 |
| MACD | 0.31 | -0.25 |
| Stochastic Oscillator | 45.09 | 12.94 |
Open Text Corp is engaged in the design, development, marketing, and sale of Information Management software and solutions. Its software allows clients to archive, aggregate, retrieve, and search unstructured information (such as documents, e-mail, and presentations). Its platform and services provide secure and scalable solutions for enterprises, SMBs, governments, and consumers around the world. The company's solutions are marketed and delivered on the OpenText Cloud Platform, which is a comprehensive Information Management platform consisting of six business clouds; Content Cloud, Cybersecurity Cloud, Application Automation Cloud, Business Network Cloud, IT Operations Management Cloud, and Analytics Cloud. Geographically, it derives maximum revenue from the United States.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.